AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment...
Rachel Johnson Terry Mamounas William Gradishar Withhold Trastuzumab in Low-Risk Patients with HER-2 Positive Breast Cancer? REFERENCE: Abstract:...
IAN SMITH, Royal Marsden Hospital, London REFERENCE: Lancet 369:29 Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for...